A Quantitative Systems Pharmacology Model of Alzheimer’s Disease Pathology and Treatment Modalities
Presented by Genentech, Hofmann-La Roche, and Rosa at the American Conference on Pharmacometrics (ACoP), November 2020
QSP modeling predicts higher naloxone doses will safely reverse more opioid overdoses and save lives.
Presented by Adamis Pharmaceuticals and Rosa at the American Conference on Pharmacometrics (ACoP), November 2020
How does mechanistic QSP modeling reduce R&D risk in data poor disease areas such as central nervous system (CNS) diseases?
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), November 2020
QSP modeling shows efficacy of an NK3R antagonist to reduce treatment induced vasomotor symptoms
Presented by Acer Therapeutics and Rosa at the American Conference on Pharmacometrics (ACoP), November 2020
Using Mechanistic Quantitative Systems Pharmacology (QSP) Models To Connect Biomarkers To Clinical Disease Activity Scores Examples In Atopic Dermatitis And Psoriasis
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), November 2020
Development of a Mechanistic Model of Keratinocyte Dynamics and Skin Barrier Function for Psoriasis Research
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), November 2020
Using Mechanistic QSP Models to Connect Biomarkers to Clinical Disease Activity Scores
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), November 2020
QSP modeling predicts higher naloxone doses will safely reverse more opioid overdoses and save lives.
Presented by Adamis Pharmaceuticals and Rosa at ABM QSP day November 2020
Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level
Published in PLoS One, 2020 Jun 16